Navigation Links
Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
Date:5/21/2009

Abstract #535 Time: 8:00AM - 12:00PM Location: Level 2, West Hall D1, W240A Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guideline F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers, A. M. Glas, S. C. Linn, L. J. Van 't Veer Date: Sunday, May 31, 2009 POSTER PRESENTATION Abstract #4036 Time: 8:00 AM - 12:00 PM Location: Level 2, West Hall C Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga, P. J. Kuppen, I. Simon, L. J. Van 't Veer, R. Tollenaar Date: Sunday, May 31, 2009 POSTER DISCUSSION Abstract #518 Time: 8:00AM - 12:00PM Location: Level 2, West Hall D1, W240A Early determination of metastatic potential in breast cancer: the 70-gene signature in small tumors M. Knauer, S. Mook, V. Retel, M. Kok, J. Wesseling, A. M. Glas, E. J. Rutgers, L. J. van 't Veer, S. C. Linn Date: Monday, June 01, 2009 POSTER PRESENTATION Abstract #11083 Time: 1:00PM - 5:00PM Location: Level 2, West Hall C Combining multi-gene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer L. Stork-Sloots, O. Krijgsman, P. Roepman, F. A. de Snoo, R. A. Bender, A. M. Glas

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown t
'/>"/>

SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
2. Agendia Joins the Personalized Medicine Coalition (PMC)
3. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
4. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
5. Agendia BV Appoints Clinical and Scientific Advisory Board
6. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
9. Agendia Appoints New Chief Financial Officer
10. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
11. Agendia Appoints VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:12/25/2014)... The report “Service Quality Management and Telco ... Type - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” ... and forecasting of revenues. , Browse 152 market ... in-depth TOC on “Service Quality Management (SQM) and Telco ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... HARBIN, China, Sept. 14 /PRNewswire-Asia-FirstCall/ -- ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... American and European fidaxomicin Phase 3 clinical trials ... (CDI) was presented at the 50th Annual Interscience ... Boston. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) ...
... CRANBURY, N.J., Sept. 14 Innophos Holdings, Inc. (Nasdaq: ... today announced that Randy Gress, Chief Executive Officer, will address ... September 30, 2010 at 8:00 a.m. (Eastern Time).   ... event, please go to www.innophos.com Investor Relations Events ...
Cached Biology Technology:Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 2Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 4Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 5Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 6Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 7Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 8Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 2Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 3Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 4Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 5Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 6Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 7
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... National Institutes of Health is making available approximately ... for graduate students and postdoctoral scholars to prepare ... that could take them outside of conventional academic ... Broadening Experience in Scientific Training (BEST) awards are ...
... Geosphere has posted additions to several themed issues: ... Geodynamics and Consequences of Lithospheric Removal in the Sierra ... Snake River Plain-Yellowstone Region and Adjacent Areas; Origin and ... other articles cover terrestrial laser scanning and the earthquake ...
... University scientist Bryan Venters, Ph.D., has shed new light ... begun to explore a possible new approach to treating ... of Molecular Physiology and Biophysics who further developed the ... of Frank Pugh, Ph.D., at Pennsylvania State University before ...
Cached Biology News:NIH announces awards to strengthen the biomedical research workforce 2NIH announces awards to strengthen the biomedical research workforce 3Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 2Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 3Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 4Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 5Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 6Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 7Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 8Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 9Study helps bring genome's 'dark matter' into light 2
...
...
Non-Receptor Tyrosine Kinase Sampler Kit 10 mu g each...
Mouse monoclonal [N7519] to NR0B2 ( Abpromise for all tested applications). Antigen: E.coli expressed recombinant full length protein (Human) NR0B2 Entrez Gene ID: 8431 Swiss Protein ID: ...
Biology Products: